+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying solbinsiran, a drug given by injection, to see how well it lowers triglycerides and other blood fat levels in adults with severe hypertriglyceridemia. This phase 2 study compares solbinsiran to a placebo to evaluate safety and effectiveness in this condition. Participants will receive two subcutaneous injections of either solbinsiran or placebo. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period includes regular assessments of lipid levels over approximately 16 to 24 weeks. During the study, participants will have blood tests to measure triglycerides and related lipid markers at baseline and follow-up visits. Researchers will also monitor drug levels in the blood to understand how the body processes solbinsiran. The main outcome is the change in triglyceride levels from the start to weeks 16-24. Safety and other lipid changes will be followed until the study ends around August 2027.

Age: 18Years +All GendersPhase 2
41 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations